These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 17558784)

  • 1. Framework analysis for the carcinogenic mode of action of nitrobenzene.
    Hsu CH; Stedeford T; Okochi-Takada E; Ushijima T; Noguchi H; Muro-Cacho C; Holder JW; Banasik M
    J Environ Sci Health C Environ Carcinog Ecotoxicol Rev; 2007; 25(2):155-84. PubMed ID: 17558784
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An evaluation of the mode of action framework for mutagenic carcinogens case study II: chromium (VI).
    McCarroll N; Keshava N; Chen J; Akerman G; Kligerman A; Rinde E
    Environ Mol Mutagen; 2010 Mar; 51(2):89-111. PubMed ID: 19708067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Postulated carbon tetrachloride mode of action: a review.
    Manibusan MK; Odin M; Eastmond DA
    J Environ Sci Health C Environ Carcinog Ecotoxicol Rev; 2007; 25(3):185-209. PubMed ID: 17763046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An evaluation of the mode of action framework for mutagenic carcinogens case study: Cyclophosphamide.
    McCarroll N; Keshava N; Cimino M; Chu M; Dearfield K; Keshava C; Kligerman A; Owen R; Protzel A; Putzrath R; Schoeny R
    Environ Mol Mutagen; 2008 Mar; 49(2):117-31. PubMed ID: 18240158
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A critical review of the literature on nitrobenzene toxicity.
    Beauchamp RO; Irons RD; Rickert DE; Couch DB; Hamm TE
    Crit Rev Toxicol; 1982; 11(1):33-84. PubMed ID: 6761067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A classification framework and practical guidance for establishing a mode of action for chemical carcinogens.
    Butterworth BE
    Regul Toxicol Pharmacol; 2006 Jun; 45(1):9-23. PubMed ID: 16530901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ochratoxin A: An overview on toxicity and carcinogenicity in animals and humans.
    Pfohl-Leszkowicz A; Manderville RA
    Mol Nutr Food Res; 2007 Jan; 51(1):61-99. PubMed ID: 17195275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epigenetic processes and cancer risk assessment.
    Preston RJ
    Mutat Res; 2007 Mar; 616(1-2):7-10. PubMed ID: 17147955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ethyl methanesulfonate toxicity in Viracept--a comprehensive human risk assessment based on threshold data for genotoxicity.
    Müller L; Gocke E; Lavé T; Pfister T
    Toxicol Lett; 2009 Nov; 190(3):317-29. PubMed ID: 19443141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. U.S. EPA's IRIS assessment of 2-butoxyethanol: the relationship of noncancer to cancer effects.
    Gift JS
    Toxicol Lett; 2005 Mar; 156(1):163-78. PubMed ID: 15705494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nitrobenzene.
    National Toxicology Program
    Rep Carcinog; 2011; 12():294-6. PubMed ID: 21860498
    [No Abstract]   [Full Text] [Related]  

  • 12. Genotoxicity effect of nitrobenzene on soybean (Glycine max) root tip cells.
    Guo D; Ma J; Li R; Guo C
    J Hazard Mater; 2010 Jun; 178(1-3):1030-4. PubMed ID: 20303656
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 4-Aminobiphenyl and DNA reactivity: case study within the context of the 2006 IPCS Human Relevance Framework for Analysis of a cancer mode of action for humans.
    Cohen SM; Boobis AR; Meek ME; Preston RJ; McGregor DB
    Crit Rev Toxicol; 2006; 36(10):803-19. PubMed ID: 17118730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating the human relevance of chemically induced animal tumors.
    Cohen SM; Klaunig J; Meek ME; Hill RN; Pastoor T; Lehman-McKeeman L; Bucher J; Longfellow DG; Seed J; Dellarco V; Fenner-Crisp P; Patton D
    Toxicol Sci; 2004 Apr; 78(2):181-6. PubMed ID: 14737005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Environmental genotoxicants/carcinogens and childhood cancer: bridgeable gaps in scientific knowledge.
    Anderson LM
    Mutat Res; 2006 Sep; 608(2):136-56. PubMed ID: 16829162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A strategy for the risk assessment of human genotoxic metabolites.
    Dobo KL; Obach RS; Luffer-Atlas D; Bercu JP
    Chem Res Toxicol; 2009 Feb; 22(2):348-56. PubMed ID: 19170655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Generalities about carcinogenesis].
    Tubiana M
    C R Biol; 2008 Feb; 331(2):114-25. PubMed ID: 18241804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluating genotoxicity data to identify a mode of action and its application in estimating cancer risk at low doses: A case study involving carbon tetrachloride.
    Eastmond DA
    Environ Mol Mutagen; 2008 Mar; 49(2):132-41. PubMed ID: 18213651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of in vivo mutation data can inform cancer risk assessment.
    Moore MM; Heflich RH; Haber LT; Allen BC; Shipp AM; Kodell RL
    Regul Toxicol Pharmacol; 2008 Jul; 51(2):151-61. PubMed ID: 18321622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypothesis-based weight of evidence: a tool for evaluating and communicating uncertainties and inconsistencies in the large body of evidence in proposing a carcinogenic mode of action--naphthalene as an example.
    Rhomberg LR; Bailey LA; Goodman JE
    Crit Rev Toxicol; 2010 Sep; 40(8):671-96. PubMed ID: 20722583
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.